Abstract
Background: Women receiving endocrine adjuvant (EA) therapy after breast cancer treatment report high rates of menopausal symptoms including vasomotor symptoms (VMS). VMS impact quality of life and can lead to treatment discontinuation and reduced survival, but existing literature evaluating symptom burden and impact is limited. The REAL-world evIdence on vasomotor and other Symptoms in menopausal womEn (REALISE) study aimed to evaluate physician and patient perceptions of symptom burden and impact in women experiencing VMS while receiving EA therapy for breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
